

November 08, 2022

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Subject: Investors Presentation on Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2022

Dear Sir/Madam,

Please find attached a copy of Company's Q2 & H1 FY23 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2022, approved by the Board of Directors in their meeting held on November 08, 2022.

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

For Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary and Legal Head
Encl.: As above



Dr. Lal PathLabs Limited (DLPL)

ENABLING
HEALTHIER
LIVES

Q2 & H1 FY23 Results Presentation

November 8, 2022

Disclaimer

By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the "Company") for use in presentations by the Company at analyst and investor meetings and does not constitute a recommendation regarding the securities of the Company. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. Neither the Company nor any of its advisors or representatives is under any obligation to update or keep current the information contained herein. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Any investment in securities issued by the Company will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not unduly rely on these forward looking statements. The Company, its advisors and representatives assume no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus under the (Indian) Companies Act, 2013 and will not be registered with any registrar of companies. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities for sale in the India. This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of the United States securities laws. This presentation and the information contained herein is being furnished to you solely for your information and may not be reproduced or redistributed to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the U.S., Canada, Australia, Japan or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of the United States or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

By reviewing this presentation, you are deemed to have represented and agreed that you and any person you represent are either (a) a qualified institutional buyer (within the meaning of Regulation 144A under the Securities Act) or (b) not a U.S. person (as defined in Regulation S under the Securities Act) and are outside of the United States and not acting for the account or benefit of a U.S. person.

Table of Contents

Dr. Lal PathLabs – At a Glance	4
Overview of Dr. Lal PathLabs	5
Key Performance Highlights	7
Financials	9
Financial Highlights	10
Operating Highlights	11
Management Commentary	12
Corporate Overview	13
Shareholding	28
Contact Us	29

Dr. Lal PathLabs – At a Glance

India's Leading & Trusted
Diagnostics Company

70+ years of experience
in the field of diagnostics

100 Mn patients serviced
in last 5 years

31 NABL accredited Labs;
2 CAP accredited Labs

**Largest*
diagnostics
chain in the
country with
PAN India
presence and
consistent track
record of
quality and
growth**

20%

3 Year Revenue
CAGR

20%

3-Year PAT
CAGR

120%

Equity Dividend
for FY 21-22

~44%

ROCE
Excl. Cash &
Investments

Rs. 419 crore (Net)

Cash & Investments as on
30th September, 22

277

Labs;
Geographically
spread out
network

4,731

Patient Service
Centres (PSC's)

5,113

Pathology &
Radiology tests;
Comprehensive
Test menu

As on March 31, 2022

*Largest on the basis of revenue and presence

Note: Figures includes Suburban Diagnostics w.e.f. 12th November 2021

Overview of Dr. Lal PathLabs

Established brand

Established consumer healthcare brand in diagnostic services



Pan-India integrated coverage

277 clinical labs (including National Reference Lab at Delhi and Regional Reference lab at Kolkata), 4,731 Patient Service Centers (PSCs) and 10,599 Pick-up Points (PUPs)*



Varied Offerings

Catalogue of 491 test panels, 2,675 pathology tests and 1,947 radiology and cardiology tests




Unique and successful operating model

Scalable model integrated through centralised IT platform allows for network expansion



Well-positioned in one of the fastest-growing segments of the Indian healthcare industry

Q2 FY23 Snapshot



* Normalised EBITDA excl. RSU, CSR

**Normalised PAT excl. notional depreciation and exceptional expenses of Rs. 14 crore

Note: Results includes Suburban Diagnostics

Key Performance Highlights

In Q2 FY23:

- Non-Covid Revenues grew by 15% Y-o-Y to Rs. 514 crore, Total Revenues higher by 7% Y-o-Y to Rs. 534 crore
- Normalised EBITDA* came in at Rs. 150 crore, a margin of 28%
- Normalised Profit After Tax** at Rs. 86 crore, a margin of 16%

A healthy balance sheet with net Cash and Cash Equivalents at Rs. 419 crore as on September 30, 2022

Focus on driving volumes through expanded network; cluster city approach working well with lot of new customers getting introduced to Dr. Lal brand


- Revenues from COVID and allied portfolio continued to decline with limited COVID caseloads across the country
- Highest ever 'Swasthfit' revenue of Rs 95 Cr achieved in Q2 FY23
- Emphasis on improving the market penetration via franchisee model, and leveraging the digital infrastructure to drive volumes and maintain the margin trajectory

* Normalised EBITDA excl. RSU, CSR

**Normalised PAT excl. notional depreciation and exceptional expenses of Rs. 14 crore

Note: Results includes Suburban Diagnostics

Non-COVID, COVID & Allied Revenue



*COVID includes RTPCR and Antibody tests; **COVID Allied 1 includes IL-6 & D-Dimer; ***COVID Allied 2 includes CRP, Ferritin & LDH

Total Covid and Covid allied contribution at 4% in Q2 FY23, 10% in Q2 FY22

Note: Revenue in Q2 23 includes Rs 40.1 Cr (Non Covid Rs 37.5 Cr, Covid Rs 2.6 Cr) of Suburban. On transition from IGAAP to IND AS, revenue adjusted as per IND AS 11

Financials

Particulars (Rs. Cr.)	Q2 FY23	Q2 FY22	Gr %	FH'23	FH'22	Gr %
Revenue	533.8	498.4	7.1%	1,036.5	1,105.0	-6.2%
Expenditure	390.0	357.0		775.2	774.6	
EBITDA	143.8	141.5		261.3	330.4	
Stock based comp., CSR cost	6.3	10.7		14.3	20.8	
Normalised EBITDA	150.1	152.2	-1.4%	275.6	351.2	-21.5%
<i>Normalised Margins</i>	<i>28.1%</i>	<i>30.5%</i>		<i>26.6%</i>	<i>31.8%</i>	
Net other Income/ (Interest)	-2.2	9.7		-2.4	19.1	
PBT	102.8	130.6	-21.3%	184.2	309.9	-40.6%
<i>Margins</i>	<i>19.3%</i>	<i>26.2%</i>		<i>17.8%</i>	<i>28.0%</i>	
PAT	72.4	96.3	-24.8%	130.6	230.0	-43.2%
<i>Margins</i>	<i>13.6%</i>	<i>19.3%</i>		<i>12.6%</i>	<i>20.8%</i>	
EPS (Basic)	8.64	11.49		15.61	27.38	
Normalised PBT*	117.0	130.6	-10.4%	210.6	309.9	-32.0%
<i>Margins</i>	<i>21.9%</i>	<i>26.2%</i>		<i>20.3%</i>	<i>28.0%</i>	
Normalised PAT*	86.2	96.3	-10.5%	156.6	230.0	-31.9%
<i>Margins</i>	<i>16.1%</i>	<i>19.3%</i>		<i>15.1%</i>	<i>20.8%</i>	


*Normalised PBT & PAT are excl. notional depreciation and exceptional expenses of Rs. 14 Cr in Q2 FY23 and 26 Cr. in FH FY23

Financial Highlights


All figures in Rs. Crore

Revenue


■ Non Covid ■ Covid




Normalised EBITDA*



Normalised PBT**



Normalised PAT**




* Normalised EBITDA excl. RSU, CSR

**Normalised PBT & PAT excl. notional depreciation and exceptional expenses of Rs. 14 crore


Note: On transition from IGAAP to IND AS, revenue adjusted as per IND AS 115.

Operating Highlights


No. of Clinical Laboratories




No. of PSCs




No. of PUPs



No. of Patients (Mn)



No. of Samples (Mn)



Note: Includes 38 Labs, 177 PSC's and 983 PUP's of Suburban Diagnostics

Management Commentary

Commenting on the results announcement, (Hony) Brig. Dr. Arvind Lal, Executive Chairman said:

“Dr Lal Pathlabs has been focused on strengthening its service capabilities and presence across multiple geographies, town classes and channels. I am happy to share with you that we have made good progress and will continue to make investments in making deeper inroads specially in Tier 2,3 & 4 cities. This will help further accelerate the shift from unorganized to organized.

In parallel we are also investing a lot in building medical excellence programs and bringing into India cutting edge technology. I am happy to announce the launch of L-CORD; India’s first Centre of Excellence on Reproductive Diagnostics.

Overall, we are encouraged by the recognition diagnostic industry has gained in the last few years especially post Covid pandemic and being leaders in the industry we continue to strengthen our position.”

Commenting on the results announcement, Dr. Om Manchanda, Managing Director said:

“Post Covid-19 pandemic, the Indian diagnostics industry has seen the entry of new players. This has further accelerated the business shift from unorganized to organized players.

Our performance trajectory continues to improve backed by increased volume flow from wellness testing, especially post the Covid-19 outbreak in addition to incremental gains from new clusters developed across Western and Eastern region. Instead of increasing the test prices, we are focusing on driving volumes to achieve scale benefits, thereby maintaining our margins. I believe our strategy here is working well and we would like to replicate the same for Suburban to bolster our leadership position in the country.

We have consistently created value for all our stakeholders throughout all these years and will endeavor to continue that, while growing and deepening our presence to touch more-and-more customers in tier II and tier III markets.”

Commenting on the results announcement, Mr. Bharath Uppiliappan, Chief Executive Officer said:

“During the quarter under review, we registered strong gains in our Non-Covid business, which grew at 14.8% Y-o-Y.

Our growth was aided by a) Swasthfit - registered its highest ever revenue b) Super specialty and medical excellence programs like Genevolve and LACE.

Suburban diagnostics continues to make progress across various key operating metrics. We continue to imbibe a lot of technology throughout the value chain. Our relentless efforts have been to improve productivity of our operating cycle to stay ahead of the competition while expanding our test menu to offer comprehensive test range.

All in all, we are in for some interesting time ahead and Dr. Lal Pathlabs is well poised to garner incremental share across geographies, town classes, channels and test portfolio.”




 *Dr Lal PathLabs*

Corporate Overview

Vision, Mission & Values

Be the most trusted
healthcare partner,
enabling healthier
lives

To be an undisputed market
leader by providing accessible,
affordable, timely and quality
healthcare, diagnostics, applying
insights and cutting-edge
technology to create value for
all stakeholders



Customer First

**Ethics &
Integrity**

Quality

Accountability

**Empathy &
Compassion**

Vibrant Outlook

Target to grow ahead of the industry


Strongly develop Rest of India geographies, through Regional Reference Labs and cluster city approach for attractive markets

Deeper Penetration within the North, East & Central Indian markets

Higher contribution from bundling of tests – ‘Swasthfit’

Evaluate best fit inorganic opportunities in South, and leverage expertise of recently acquired Suburban brand in West

DLPL Strategy for future growth



DLPL Strategy for future growth



Strengthen Existing Operations

- Improve breadth of diagnostic testing
- Cutting edge technology
- Preventive healthcare screening
- Chronic & Lifestyle disease mgmt. services
- Expand reach in corporate segment

- Boosting quality & reliability standards
- Improving turnaround times for testing
- Grow basic radiology practice
- Online initiatives and data analytics
- Investment in branding

Expansion in Offering



Expand management of hospital based and clinical laboratories

- Focus city & cluster approach
- Set up more clinical laboratories
- Set up Regional Reference Laboratories
- Consider alliances and acquisitions

- Tap incremental contracts for in-sourcing test of hospitals and other clinical laboratories
- Tap polyclinics

Geographic expansion



Leveraging digital infrastructure to make life easier for patient

Digital Lab


- Self Registration Kiosk for patients
- Integrated payment gateway for online payment
- Self Report printing Kiosks for 24 by 7 Report printing similar to a bank ATM

e-Commerce

- Online test / health package booking
- Online payment, order related notifications at various touch points
- Integrated Cross Channel communication with strong automated backend using cloud, predictive analytics & AI
- Phlebo Mobile App for home collection booking along with route plan.

Mobile app

- Test booking, view and download current and historical test reports
- Trend chart along with Cumulative Reporting
- Find a Lab near you
- Self Monitoring – My Wellness



Logistics Automation

- Field Executive Mobile App for Route Traceability & Field Executive Tracking
- Real Time visibility of patient samples

Lab Operations Automation

- Totally integrated Track with centralized LIMS for higher Output and faster processing, built in analytics and Business Intelligence capabilities

Business Continuity Plan

- 'Multi Site' model
- Quick recovery in case of disaster
 - Real time Data Replication between sites
 - Centrally Hosted and real time monitored

Consistent investments in R&D

DSIR recognized In House R&D unit with an experienced team of research scientists and doctors




 जवाहरलाल नेहरू विश्वविद्यालय
Jawaharlal Nehru University

Jawaharlal Nehru University for development of diagnostics kit for detection of mycobacterium tuberculosis and mycobacterial species

CSIR-Institute of Genomics and Integrative Biology for acquisition of know-how for 27 diagnostic assays



R&D Collaboration with marquee institutions



Genevolve: The Genomics initiative

GENEVOLVE brings the dawn of a new era of Genomic testing!



New Tests

- Sperm DNA
- Y Chromosome



New Tie-ups

- Caris MI (USA)
- Caris Tumor Seek



ONCOPATH

- Niche Segmentation

Genevolve: Genomics division focuses on Genetic testing

Offers wide range of key tests related to Oncogenomics, Neurogenomics, Rare disease & Pre-natal/ Post-natal

Tests are carried out using cutting edge technologies such as Next Generation Sequencing (NGS), MLPA, ddPCR, FISH & Sanger Sequencing among others

PAN India network of clinical laboratories, collection centers and pick- up points makes Dr. Lal PathLabs the most reliable genetic testing service provider in India

In-house adoption of Digital Histopathology

Reporting of Digital Breast cancer Panels using AI based algorithms

Digital Histopathology for remote routine reporting



Opportunities created by Digital Histopathology

- Enhanced access to second opinion, synchronous review of slides
- Enhanced quality of reporting
- Potential for insourcing services
- Leveraging Artificial Intelligence for Histopathology
- Potential for de-centralization of histopathology reporting

Highest Quality Standards in the Industry

Best in the Industry CAP Proficiency Testing Score at 97.9% for National Reference Lab

Consistently high EQAS Performance Testing Score at 98.6% for Satellite Labs

NABL Accreditation granted to 18 Labs for processing Covid-19 samples


**Real time quality
control monitoring**

**Risk based quality
assurance
framework**

**100+ Quality
improvement
meetings on a daily
basis with the
network partners**

**Digitally enabled
solutions
implemented for
quality audits and
trainings**

Realtime Quality Control (QC) via automated review and analysis



Best in class Logistics and Supply Chain management



Real time
sample
tracking

Real time
Field
Executive
tracking

Automated
Cash collection
process with
clients

Productivity
and route
planning
visibility

Real time
service
monitoring
Control tower

Enhanced Customer Experience in Home Collection



Auto Routing engine to dynamically allocate the booking to nearest available phlebotomist


Real time phlebo visibility to the patient



Variable model which grows with business volume



Automated and scalable system



Real time slot confirmation to patient



ECG at home service launched in select cities



Experienced Management team

(Hony.) Brig. Dr. Arvind Lal

Executive Chairman




Dr. Om Manchanda

Managing Director



Dr. Vandana Lal

Whole-time Director



Bharath Uppiliappan

Chief Executive Officer



Ved Prakash Goel

Group Chief Financial Officer



Shankha Banerjee

Chief Executive Officer (Group Cos)



Munender Soperna

Chief Information Officer



Rajat Kalra

Company Secretary and Compliance Officer



Manoj Garg

Group Chief Human Resources Officer



Key Awards & Recognition



Business Standard Star
SME of the year 2022



Best Brands
Healthcare 2022



GAPIO Excellence in
Diagnostics Award
2022



Financial Express CFO
of the year 2022



CFO100 Roll of
Honour 2022



CSR Award 2022



ICICI Lombard &
CNBC TV18 India
Risk Management
Awards 2022 –
Healthcare



Dr. Om Manchanda
honoured and
awarded as
'Healthcare
Personality of the
Year, 2020' by FICCI



EY Entrepreneur
of The Year 2019
– Life Sciences &
Healthcare



Data Quest
Technology Award
2015 – Excellence
in Implementation
of Technology



VC Circle
Healthcare
Summit 2013 –
Best Diagnostic
Company



Computerworld
Honors Laureate
Program, 2012



Frost and Sullivan
4th Annual India
Healthcare
Excellence Award,
'Diagnostic Service
Provider Company
of the Year 2012'



Franchise India
Excellence Award
in Hall of Fame
Category (2011,
2012)




Franchisor of the
Year
(Healthcare) -
Franchise Plus
Awards 2010



Padma Shri –
(Hony) Brig. Dr.
Arvind Lal (2009)

Shareholding as of 30th September, 2022



*Mutual Funds includes Alternate Investment Funds as well

Contact Us

About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brand in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 491 test panels, 2,675 pathology tests and 1,947 radiology and cardiology tests as on March 31, 2022.

As on March 31, 2022, DLPL's has 277 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 4,731 Patient Service Centers (PSCs) and 10,599 Pick-up Points (PUPs). In FY21 & FY22, DLPL collected and processed approximately 49.7 million samples and 66 million samples from approximately 20.3 million and 27.3 million patients, respectively.

Additional information on Dr. Lal PathLabs Limited: Corporate Identification No: L74899DL1995PLC065388

Website: <https://www.lalpathlabs.com>

**For further
information
please contact:**

Ved Goel / Rajat Kalra

Dr. Lal PathLabs Limited

Tel: +91 124 301 6500

Fax: +91 124 423 4468

E-mail: ved.goel@lalpathlabs.com / rajat.kalra@lalpathlabs.com

Siddharth Rangnekar / Nishid Solanki

CDR India

Tel: +91 22 66451209 / 1221

Fax: +91 22 66451213

Email: siddharth@cdr-india.com / nishid@cdr-india.com